Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00193908 | Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine ("Sorbolene") Cream | PHASE3 | COMPLETED | 333 | — | — | Mar 1, 2004 | Oct 1, 2008 | May 14, 2009 | 12 | Australia |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cavilon (TM) Durable Barrier Cream | DRUG | Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation. |
| Sorbolene | DRUG | Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation |
| Radiotherapy | RADIATION | Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol |
Inclusion Criteria: * Ages 18 or more years * Post total mastectomy * Planned dose at least 45 Gy in 25 fractions * ECOG 0-2 * Able to attend weekly during treatment for review and photo and for up to 6 weeks after radiotherapy * Patients capable of childbearing using adequate contraception * Writt...